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423* Consanguinity and cystic ﬁbrosis: the end of a myth.
Demographic analysis of a genealogical database in
Brittany (France)
N. Pellen1,2,3, G. Bellis2, L. Gue´ganton1, C. Rollet3, G. Rault1. 1CF Center of
Perharidy, Roscoff, France; 2INED, Paris, France; 3University of Versailles Saint
Quentin en Yvelines, Guyancourt, France
The aim of this study is to show that the historical data, through genealogies, can
help understanding the spreading process of the CFTR mutations on a determined
territorial area, particularly affected by the disease. We will speciﬁcally analyze the
part of consanguinity.
The panel is composed of 705 CF patients who were born or have lived in Brittany
within the past 50 years. Since these patients have been taken care of by local caring
centers, we know all their genetic and clinical characteristics. Moreover, thanks to
the registry ofﬁces and the local archives we managed to track their pedigrees,
which led to the identiﬁcation of an ancestral population of 165 000 individuals.
The database, validated by the CNIL (National commission for data protection),
works with an algorithm which can ﬁnd the parental relationships between the
individuals.
The results presented in this study are limited to the genealogical links found
between the patients who carry the most common mutations in Brittany (F508del,
G551D, 1078del) in the heterozygous compound state. The 3 groups are similar
in terms of results: we ﬁnd few close inbreeding (below 4 generations). However,
there is much remote kinship (at least 7 generations). If we compare a group of
carriers and a group of non-carriers, among the carriers the coefﬁcient of kinship
is much higher. Therefore patients have a common gene that they inherited from a
small number of people. It is the presence of those genes in a sedentary population,
with a restricted marriage market, that leads to an elevation of incidence for CF as
well as the higher frequency of local mutations.
Supported by: ANRT, CHM Foundation.
424* Differences in disease severity of F508del homozygotes across
European countries
A. Zolin1, L. Viviani1, H. Olesen2, E. Kerem3, A. Bossi1, European Cystic Fibrosis
Registry. 1Statistica Medica e Biometria “G.A. Maccacaro”, Milan, Italy; 2Aarhus
University Hospital Skejby, Cystic Fibrosis Center Skejby, Arhus, Denmark;
3Hadassah-Hebrew University Medical Center, Mount Scopus, Department of
Pediatrics, Jerusalem, Israel
Introduction: Signiﬁcant phenotypic variation occurs even among patients carrying
identical CFTR genotype. This suggests that other factors, such as modiﬁer genes
and environmental factors, contribute to the determination of CF severity. The aim
of this study is to compare clinical characteristics of patients carrying the common
genotype (F508del/F508del) across European countries.
Patients: We analysed data from 6663 F508del homozygous patients from 15 coun-
tries, included in the European CF Registry in the year 2007. The frequency
of F508del homozygotes varies from 70% in Denmark to 11% in Israel. We
evaluated differences in clinical characteristics of CF including pulmonary function,
anthropometric data, complications, and therapy.
Results: Statistically signiﬁcant (p< 0.01) differences were found across countries
in median FEV1% (59−91%), proportion of patients with BMI< 2 SDS (4−37%),
prevalence of chronic Pseudomonas aeruginosa infection (2−56%), meconium ileus
(3−19%), liver disease (2−36%), use of inhaled antibiotics (3−95%) and use of
inhaled rhDNase (4−85%).
Discussion: The differences in disease severity found among patients with the same
genotype but living in different countries suggest that environmental and therapeutic
factors play an important role in determination of CF disease severity. These could
be also due to different therapeutic strategies. Further studies are needed in order
to determine if these differences are due to lack of standardization of variable
deﬁnitions, to missing data points or to true differences in patients care in different
countries. Standardization of care according to countries where disease is less severe
might be needed.
425* Incidence and risk factors for frequent pulmonary exacerbation
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Introduction: While risk factors for individual pulmonary exacerbations (PE) have
been identiﬁed there is little data regarding the distribution and factors associated
with recurrent PE.
Methods: All PE requiring IV antibiotics occurring in patients attending an adult CF
center over 3 years were examined. Patients were deﬁned as frequent exacerbators
(FE) if they experienced 3 events/evaluable years.
Results: Of the 232 patients identiﬁed: 40% experienced no PE, 27% 1/year, 14%
1−2/year, 12% 2−4/year, 5% 4−6/year and 3% 6 PE/year. FE had similar median
age and sex distribution. FE status was more common with advancing airway disease
(AD): 21/29 with severe AD were FE, whereas 13/107 with moderate AD and 2/87
mild AD were FE. FE were more likely to be infected with; P. aeruginosa risk
ratio (RR) 2.68, B. cenocepacia RR 2.70 and S. maltophilia RR 3.55. Patients were
more likely to be on disease modifying regimens including; inhaled tobramycin
RR 2.22, colistin RR 2.99, DNase RR 4.18, oral azithromycin RR 2.18 and enteral
feeds RR 7.64. FE, however, were more likely to be treated with oral steroids RR
3.2, inhaled steroids RR 2.05 and proton pump inhibitors RR 3.18. In multivariate
analysis, factors independently associated with FE included; advanced AD, chronic
P. aeruginosa, B. cenocepacia or S. maltophilia infection, oral corticosteroids and
CF-related diabetes. Rate of FEV1 decline/year was accelerated in FE; −8.52% vs
−0.84%. Furthermore, RR of death was 6.68 in FE, p< 0.001.
Conclusions:While more common in those with advanced disease, FE are observed
at all stages of disease and FE status correlates with increased rate of disease
progression.
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FEV1 has long been the gold standard used to monitor CF lung disease, even
though there is uncertainty as to whether it can adequately detect disease onset and
progression, especially in children. As part of the Wisconsin CF Neonatal Screening
Project, we assessed the evolution of symptoms, signs, and quantitative measures
of lung disease to determine the sensitivity of various surrogates. From 149 RCT-
enrolled children, we selected those who had undergone a chest CT scan per study
protocol and compared Brody scores of severity to their most recent PFT data,
Wisconsin CXR scores (WCXR), and parental reports of symptoms in the prior
year. We calculated sensitivity of the clinical measures to detect a “high” chest
CT value, i.e., a score worse than the median chest CT score. Eighty-two children
had a chest CT at mean age of 11.5 (range 6−17) years; of these, 72 had CXR
and 77 had PFT data. FEV1 was considered abnormal if it was <82.4% predicted.
We found that the sensitivity of an abnormal FEV1 to detect a “high” CT score
was only 40%, and other PFT surrogates including FEV1/FVC (38%), FEV25−75
(38%), and RV/TLC (53%) were also inadequate. In contrast, the sensitivity of an
abnormal WCXR score was 97%. Additionally, the sensitivity of parent report of
daily cough and a positive sputum culture for Pseudomonas aeruginosa each had
a sensitivity of 56%. In conclusion, FEV1 is not sensitive in predicting chest CT
abnormalities in children with CF. It has limited usefulness as an outcome measure
in research studies and cannot be relied upon clinically. However, quantitative chest
radiography correlates well with CT scores (r = 0.82; p< 0.001) and has excellent
sensitivity.
